Fujifilm/Kyowa biosimilar shows equivalence to Humira

Fujifilm Kyowa Kirin Biologics Co. Ltd. said biosimilar candidate FKB327 met the primary endpoint in a global Phase III trial to treat moderate to severe rheumatoid arthritis by showing equivalence to reference product Humira adalimumab, as measured by ACR20 response.

Fujifilm Kyowa Kirin is a JV between Fujifilm Holdings Corp. (Tokyo:4901) and Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151). ...